Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
TYK Medicines, Inc. Class H ( (HK:2410) ) has provided an announcement.
TYK Medicines, Inc announced positive early-phase clinical study results for three of its CDK inhibitor candidates at the ESMO Congress 2025. The study, particularly focusing on TYK-00540, showed promising safety and efficacy results in patients with advanced solid tumors, including those resistant to existing CDK4/6 inhibitors. The results indicate potential advancements in treatment options for hormone receptor-positive, HER2-negative breast cancer, which could enhance the company’s positioning in the oncology market.
The most recent analyst rating on (HK:2410) stock is a Buy with a HK$31.60 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
More about TYK Medicines, Inc. Class H
TYK Medicines, Inc is a pharmaceutical company based in the People’s Republic of China, focusing on the development of cyclin-dependent kinase (CDK) inhibitors. These inhibitors are primarily targeted at treating various advanced cancers, including breast cancer, ovarian cancer, and non-small cell lung cancer.
Average Trading Volume: 11,661,460
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$5.74B
Find detailed analytics on 2410 stock on TipRanks’ Stock Analysis page.